Clinical trials: Obesity Overweight
Obesity
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight.
- Trial name
- OUTSTEP-1 (NCT07154238)
- Testing
- No treatment given
- Where
- Germany
- Volunteers
- 2,546 people
- Sponsor
- Novo Nordisk A/S
Obese, Sleep Apnea, Obstructive
Eval EarlySense Bet Lowenstein Sleeplab
The study objective is to collect heart rate, respiration rate and motion data of patients admitted to sleep lab and to determine the accuracy level of the EarlySense system vs.
- Conditions
- Obese, Sleep Apnea, Obstructive, Central Apnea, Sleep Disorders
- Trial name
- NCT01978340
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- EarlySense Ltd.
Hypertension, Overweight or Obesity
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
- Trial name
- NCT06948435
- Testing
- Orforglipron
- Where
- 99 sites in United States, Argentina and 9 more
- Volunteers
- 487 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight
The purpose of this clinical study is to find out if NNC0662-0419 is safe and effective to be taken together with other medicines, like birth control pills, and emptying of the stomach in women not able to become pregnant living…
- Trial name
- NCT07525791
- Testing
- NNC0662-0419, Oral contraceptive, Acetaminophen
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose
Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with…
- Trial name
- PRADO (NCT00405808)
- Testing
- Rimonabant
- Where
- 27 sites in Austria, Belgium and 25 more
- Volunteers
- 2,666 people
- Sponsor
- Sanofi
Obesity, Type 2 Diabetes Mellitus in Obese
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT05890950
- Testing
- K-757 and K-833
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- TriGemX Bio, Inc.
Obesity
Dose-Ranging Study of SKF7® for Obesity
This study has been designed as a randomized, double blinded, multi-centric, placebo controlled and phase II dose-ranging study.
- Trial name
- NCT05851599
- Testing
- SKF7® Labisia pumila standardized extract
- Where
- 6 sites in Malaysia
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Medika Natura Sdn Bhd
Overweight, Obesity
Weight-loss Treatment Through Smartphone-assisted Dietary Coaching
The purpose of this study is to evaluate the effectiveness and feasibility of weight loss counselling via a smartphone-app for patients with overweight/obesity in a 1-year long pilot study.
- Trial name
- Oviva (NCT02694614)
- Testing
- smartphone-assisted dietary coaching
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- Oviva AG
Obesity, Overweight
Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects
A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects.
- Trial name
- NCT00785408
- Testing
- AC2307
- Where
- 18 sites in United States
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Overweight, Obesity
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- STEP7 (NCT04251156)
- Testing
- Semaglutide
- Where
- 33 sites in Brazil, China and 2 more
- Volunteers
- 375 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
- Trial name
- NCT05794581
- Testing
- CT-868, Victoza
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Metabolism and Nutrition Disorder, Obesity
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of the trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects being overweight or with obesity
- Trial name
- NCT02835235
- Testing
- NNC9204-0530
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects.
- Trial name
- NCT06184568
- Testing
- IBI362, Semaglutide
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight and Obesity
A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants
This is a Phase 2b, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of TE-8105 in adults with overweight or obesity…
- Trial name
- NCT07857473
- Testing
- TE-8105 MAD Cohort 1, TE-8105 MAD Cohort 2, TE-8105 MAD Cohort 3
- Where
- 2 sites in Australia
- Volunteers
- 204 people
- Sponsor
- Immunwork, Inc.
Difficult or Failed Intubation, Obesity, Morbid
Evaluation of Preoperative Nasoendoscopy to Predict Difficult Intubation
Despite the availability of different methods for airway assessment, unexpectedly difficult intubations occur at a frequency of up to 15%.
- Trial name
- NCT05043779
- Testing
- Awake Airway Nasoendoscopy
- Where
- Qatar
- Volunteers
- 30 people
- Sponsor
- Hamad Medical Corporation
Obesity, Overweight
A Study of GZR18 Injection in Obese/Overweight Patients
This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.
- Trial name
- NCT06256562
- Testing
- GZR18
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Overweight and Obesity
Electrical Vestibular Stimulation (VeNS): Assessment of AMPK & SIRT1 Following Repeated Usage
The vestibular system which is responsible for balance and equilibrium constitutes our sixth sense. Metabolic Syndrome is a constellation of metabolic abnormalities characterized by obesity, insulin resistance (diabetes…
- Trial name
- NCT04433273
- Testing
- Electrical vestibular nerve stimulation
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Obesity, Diabetes Mellitus Type 2
Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus
The purpose of this study is to explore the mode of action of topiramate in the treatment of obese and diabetic patients by testing association between genetic variations within candidate genes or chromosomes (thread like…
- Trial name
- NCT00304603
- Testing
- No intervention
- Volunteers
- 1,145 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07868354
- Testing
- Tirzepatide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Healthy Overweight Obese
The Effect of Gelesis100 on the Pharmacokinetics of Metformin
The purpose of this study is to determine the effect of Gelesis100 on the absorption of metformin both with and without a meal.
- Trial name
- NCT02524821
- Testing
- Gelesis100, Metformin
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gelesis, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.